Neuren Pharmaceuticals Ltd (AU:NEU) — Market Cap & Net Worth

$1.70 Billion USD · AU$2.40 Billion AUD · Rank #6811

Market Cap & Net Worth: Neuren Pharmaceuticals Ltd (NEU)

Neuren Pharmaceuticals Ltd (AU:NEU) has a market capitalization of $1.70 Billion (AU$2.40 Billion) as of September 20, 2026. Listed on the AU stock exchange, this Australia-based company holds position #6811 globally and #161 in its home market, demonstrating a 2.33% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuren Pharmaceuticals Ltd's stock price AU$20.68 by its total outstanding shares 126639526 (126.64 Million). Also see how large is Neuren Pharmaceuticals Ltd's balance sheet for a full breakdown of the balance sheet.

Neuren Pharmaceuticals Ltd Market Cap History: 2015 to 2026

Neuren Pharmaceuticals Ltd's market capitalization history from 2015 to 2026. Data shows growth from $206.09 Million to $1.85 Billion (23.96% CAGR). Also see cash flow conversion of Neuren Pharmaceuticals Ltd for how efficiently the company converts equity into cash flow.

Index Memberships

Neuren Pharmaceuticals Ltd is a constituent of 3 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
S&P/ASX All Australian 200 AXAT	$1.88 Trillion	0.09%	#126 of 200
S&P/ASX 300 AXKO	$2.13 Trillion	0.08%	#140 of 300
ASX Small Ordinaries AXSO	$292.43 Billion	0.58%	#54 of 200

Weight: Neuren Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Neuren Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Neuren Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check NEU live share price for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

5.25x

Neuren Pharmaceuticals Ltd's market cap is 5.25 times its annual revenue

Industry average: 3828.66x Lower than industry average

Latest Price to Earnings (P/E) Ratio

7.89x

Neuren Pharmaceuticals Ltd's market cap is 7.89 times its annual earnings

Industry average: 1.69x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2015	$206.09 Million	$1.67 Million	-$13.40 Million	123.19x	N/A
2016	$103.94 Million	$3.15 Million	-$12.01 Million	33.00x	N/A
2017	$286.74 Million	$631.00K	$3.29 Million	454.42x	87.21x
2018	$125.45 Million	$13.99 Million	$3.07 Million	8.97x	40.82x
2019	$222.22 Million	$495.00K	-$10.82 Million	448.93x	N/A
2020	$115.14 Million	$717.00K	-$9.19 Million	160.59x	N/A
2021	$337.81 Million	$3.20 Million	-$7.79 Million	105.67x	N/A
2022	$712.36 Million	$14.55 Million	$184.00K	48.95x	3871.54x
2023	$2.24 Billion	$231.93 Million	$157.08 Million	9.65x	14.24x
2024	$1.12 Billion	$213.24 Million	$142.04 Million	5.25x	7.89x

Competitor Companies of NEU by Market Capitalization

Companies near Neuren Pharmaceuticals Ltd in the global market cap rankings as of September 20, 2026. Review Neuren Pharmaceuticals Ltd tangible equity quality to assess the quality of the company's equity after excluding intangible assets.

Key companies related to Neuren Pharmaceuticals Ltd by market ranking:

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#189	Vertex Pharmaceuticals Inc	NASDAQ:VRTX	$128.84 Billion	$508.34
#340	Regeneron Pharmaceuticals Inc	NASDAQ:REGN	$79.38 Billion	$784.85
#459	CSL Ltd	AU:CSL	$60.28 Billion	AU$175.59
#505	Moderna Inc	NASDAQ:MRNA	$54.14 Billion	$154.04

Neuren Pharmaceuticals Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, Neuren Pharmaceuticals Ltd's market cap moved from $206.09 Million to $ 1.85 Billion, with a yearly change of 23.96%.

Year	Market Cap	Change (%)
2026	AU$1.85 Billion	+11.12%
2025	AU$1.67 Billion	+48.88%
2024	AU$1.12 Billion	-49.94%
2023	AU$2.24 Billion	+214.09%
2022	AU$712.36 Million	+110.88%
2021	AU$337.81 Million	+193.39%
2020	AU$115.14 Million	-48.19%
2019	AU$222.22 Million	+77.14%
2018	AU$125.45 Million	-56.25%
2017	AU$286.74 Million	+175.86%
2016	AU$103.94 Million	-49.57%
2015	AU$206.09 Million	--

End of Day Market Cap According to Different Sources

On Sep 20th, 2026 the market cap of Neuren Pharmaceuticals Ltd was reported to be:

Source	Market Cap
Yahoo Finance	$1.70 Billion USD
MoneyControl	$1.70 Billion USD
MarketWatch	$1.70 Billion USD
marketcap.company	$1.70 Billion USD
Reuters	$1.70 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Neuren Pharmaceuticals Ltd

AU:NEU Australia Biotechnology

Market Cap

$1.85 Billion

AU$2.62 Billion AUD

Market Cap Rank

#6811 Global

#161 in Australia

Share Price

AU$20.68

Change (1 day)

+0.68%

52-Week Range

AU$11.28 - AU$23.64

All Time High

AU$25.11